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OBJECTIVE — To determine the relationships among large, small, and autonomic ﬁber
neurophysiological measures in a cross-sectional study of patients with diabetes.
RESEARCH DESIGN AND METHODS — We assessed 130 individuals: 25 healthy
subjects and 105 subjects with diabetes. Subjects were classiﬁed by the presence or absence of
neuropathy by physical examination. All subjects underwent autonomic testing, nerve conduc-
tion studies, quantitative sensory testing, and nerve-axon reﬂex vasodilation in addition to
quantiﬁable neurological examination and symptom scores. Correlation and cluster analysis
were used to determine relationships between and among different neurophysiological testing
parameters.
RESULTS — Results of neurophysiological tests were abnormal in patients with clinical evi-
dence of diabetic neuropathy compared with results in healthy control subjects and in those
without neuropathy (P  0.01, all tests). The correlations among individual tests varied widely,
both within (r range 0.5–0.9, NS to 0.001) and between test groups (r range 0.2–0.5,
NS to 0.01). A two-step hierarchical cluster analysis revealed that neurophysiological tests do
not aggregate by typical “small,” “large,” or “autonomic” nerve ﬁber subtypes.
CONCLUSIONS — The modest correlation coefﬁcients seen between the different testing
modalities suggest that these techniques measure different neurophysiological parameters and
are therefore not interchangeable. However, the data suggest that only a small number of
neurophysiological tests are actually required to clinically differentiate individuals with neurop-
athy from those without. The natural clustering of both patients and healthy control subjects
suggests that variations in the population will need to be considered in future studies of diabetic
neuropathy.
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M
icrovascular complications of dia-
betes, which include retinopathy,
neuropathy, and nephropathy are
majorcontributorstomorbidityandmor-
tality. Although neuropathy severity is re-
lated to duration and degree of glycemic
control, individual subjects may have
widely disparate clinical presentations
despite similar risk factors. Neuropathy
progression preferentially affecting nerve
ﬁber subtypes may explain some clinical
heterogeneity, but different neurophysio-
logical tests are required to identify dys-
function of different nerve populations in
diabetes.
Nerve conduction studies, assessing
large myelinated ﬁbers, are widely used
both in clinical practice and as end points
in longitudinal investigations of diabetic
neuropathy (1,2). Damage to small thinly
and unmyelinated nerves or autonomic
ﬁbers can be measured by quantitative
sensory testing, autonomic testing, and
laser Doppler ﬂowmetry (3–6). To date,
few investigators have examined the rela-
tionships between different measures of
neurophysiological function in diabetic
and other peripheral neuropathies
(4,7–10).
A cross-sectional study of diabetic
neuropathy was used to determine the
relationships among large, small, and
autonomic ﬁber neurophysiological mea-
sures. We hypothesized that measures as-
sessing similar neurophysiological
functions would correlate and cluster to-
gether along typical nerve ﬁber subtypes
(small, large, or autonomic). In addition,
we determined the sensitivity and speci-
ﬁcity of these neurophysiological mea-
sures using the Neuropathy Disability
Score (NDS) as a gold standard (11). Be-
causethisclinicalmeasureisweightedto-
ward large ﬁber assessment, we
hypothesized that neurophysiological
tests of large ﬁber function would have
higher sensitivity and speciﬁcity than
measures of small ﬁber or autonomic
function.
RESEARCH DESIGN AND
METHODS— We studied a total of
130 subjects: 25 healthy subjects without
diabetes and 105 subjects with diabetes.
The study protocol was approved by the
Beth Israel Deaconess Medical Center In-
stitutional Review Board, and all subjects
gave their informed consent. Exclusion
criteria included symptomatic peripheral
arterial disease, congestive heart failure,
cardiac arrhythmias, stroke, end-stage re-
nal failure, uncontrolled hypertension,
severe hyperlipidemia, chronic liver dis-
ease, or other chronic medical condition
requiring ongoing active treatment. All
subjects were studied at a single institu-
tion, with the same examiners at each
visit. Each test was administered by a
trained technician, in a random testing
order, without knowledge of other test
results to reduce bias. Detailed anthropo-
morphic measurements were taken at
each visit, and peripheral venous blood
was sent for routine hematology and
chemistry tests (including complete he-
patic, renal, and other metabolic testing
panels) under fasting conditions.
Symptoms and examination
Subjects completed the Neuropathy
Symptom Score (NSS) questionnaire
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quantiﬁed by the NDS (11,13). In brief,
the NDS grades neuropathy from scores
of 0 (no neuropathy) to 28 (severe neu-
ropathy). Reﬂexes are graded at the
knee and ankle for a maximum of eight
points if areﬂexic. Sensory tests include
pinprick sensation, light touch, vibra-
tion, and temperature perception. A
score is given according to the anatomic
location at which the patient can iden-
tify the introduced stimulus. If the pa-
tient perceives the stimulus at all levels,
ascoreof0isgiven.Ascoreof1isgiven
if the patient fails to perceive the stim-
ulus at the base of the toe, 2 at the mid-
foot,3attheheel,4atthelowerleg,and
5 if at or above the knee level. The av-
erage score of both feet is entered as the
sensory score. An NDS score of 0–2 was
deﬁned as “no neuropathy,” scores 3
were considered to indicate “neuropa-
thy.” The NDS score was used as the
gold standard against which other tests
were compared. A set of 12 Semmes-
Weinstein monoﬁlaments were used
(ranging from 2.83 to 10 g; Stoelting,
Wood Dale, IL) to determine the cuta-
neous perception threshold at the plan-
tar surface of both great toes. Starting
with the 2.83 g, each monoﬁlament was
applied a single time to the plantar sur-
face of the great toe, held for 1.5 s, and
removed.Themonoﬁlamentweightwas
increased until the subject reported de-
tecting the monoﬁlament. This testing
was repeated for both legs.
Quantitative sensory testing
Thermal testing was performed using a
Medoc TSA-II thermal and vibratory ana-
lyzer(WRMedicalElectronics,Stillwater,
MN). The method of limits was used for
detection of 1) warmth, 2) cool, 3) heat
pain, 4) cold pain on the right thenar em-
inence of the hand and dorsum of the
foot, and 5) vibration detection on the
right thumb and right great toe (14,15).
In brief, three repetitions of the same
stimulus were applied with standard in-
structions with maximal heat stimulation
of 50°C and cold of 0°C to avoid cutane-
ous injury. If response variability was
10%,subjectsweregivenabreakbefore
retesting.
Nerve conduction studies
Nerve conduction studies were per-
formed using a Viking IIIP electromyo-
graph (Viasys Healthcare, Madison, WI)
by the same trained technician for all pa-
tients. Peroneal and sural nerve conduc-
tionstudieswereperformedontheleftleg
using standard methodologies (1). Re-
sults of the peroneal motor conduction
velocity, peroneal compound muscle ac-
tion potential, sural sensory conduction
velocity, and sural sensory nerve action
potential (SNAP) were reported for all in-
dividuals. Individuals without recordable
responses were assigned amplitudes of 0
and the lowest measured velocity and
longest distal latency of any subject.
Autonomic testing
Subjects had continuous beat-to-beat
blood pressure and electrocardiography
monitoring during autonomic testing.
Cardiovagal function was assessed by the
heart rate response to deep respiration
andtheheartrateresponsetotheValsalva
maneuver (16). Sympathetic adrenergic
functionwasmeasuredbythebloodpres-
sureresponseduringphase2andphase4
of the Valsalva maneuver, and the hemo-
dynamic response to passive 60° upright
tilt for 10 min (16,17).
Laser Doppler ﬂowmetry
After20minofadjustmenttotheambient
temperature (23–24°C), the blood ﬂow
responses to iontophoresis of 1% acetyl-
cholinechloridesolutionwereassessedat
the volar surface of the forearm and at the
dorsum of the foot with two single point
laser Doppler probes and a DRT4 laser
Doppler blood ﬂow monitor (Moor In-
struments, Millwey, Devon, U.K.) using
standard protocols (18,19). The baseline
blood ﬂow was measured for 40 s, fol-
lowedby60sofiontophoresisat200A.
The vasodilatory response was measured
for90safteriontophoresisinendothelial-
dependent (direct blood ﬂow) and -inde-
pendent (axon reﬂex–mediated blood
ﬂow) regions.
Statistical analysis
Results are expressed as means  SD.
Variables were compared by ANOVA
with Tamhane T2 post hoc tests. Receiver
operator characteristic (ROC) curves
were generated for each test to determine
sensitivity and speciﬁcity versus the clin-
ical diagnosis of neuropathy (NDS 2).
Groups of subjects (independent of the
diagnosis of diabetes and neuropathy)
with similar responses to neurophysio-
logical variables and physical examina-
tion ﬁndings were categorized using two-
step hierarchical cluster analysis.
Clustering was performed using the
Schwarz Bayesian information criterion
with log-likelihood measures for proba-
bility distribution of variables. The con-
tributionofeachvariabletothelikelihood
of cluster assignment was determined.
Dendrograms of the cluster linkage be-
tween variables were calculated using the
Wardmethod,withzscorescalculatedfor
each variable. Statistical analysis was per-
formed using SPSS (version 15.0; SPSS,
Chicago, IL).
Table 1—Subject demographics and characteristics
Healthy control
Diabetes with
no neuropathy
Diabetes with
neuropathy
Age (years) 49  16.6 52.3  15.8 63.7  9.5*†
Sex (male/female) 12/13 20/26 2326
BMI (kg/m
2) 28.2  6.2 32.4  8.6 31.2  6.3
Height (m) 1.70  0.09 1.68  0.08 1.69  0.10
Weight (kg) 82  19 92  23 89  19
Systolic blood pressure (mmHg) 118  12 122  13 130  16*†
Diastolic blood pressure (mmHg) 73  97 3  87 3  8
Heart rate (bpm) 66  97 0  10 69  11
Diabetes type (1/2) NA 33/14 37/11
Duration diabetes (years) NA 13.1  10.3 16.4  11.9
A1C (%) 5.5  0.3 7.2  1.0* 7.0  0.9*
Total cholesterol (mmol/l) 195  31 160  38* 168  40*
Triglycerides (mmol/l) 107  50 124  94 135  84
HDL cholesterol (mmol/l) 61  17 57  19 57  14
LDL cholesterol (mmol/l) 114  31 78  31* 86  34*
NSS 0.2  0.5 0.7  1.0 4.5  3.7*†
NDS 0.2  0.5 0.4  0.8 6.3  5.3*†
DataaremeansSD.Characteristicsofthestudygroupswerecomparedbyone-wayANOVAwithTamhane
T2 post hoc tests. Diabetes type and duration were analyzed by 
2 and unpaired t tests accordingly. NA, not
applicable. *P  0.01 vs. healthy control subjects; †P  0.01 vs. diabetes without neuropathy.
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Demographics
The basic demographic information for
subjects is shown in Table 1. A total of 25
healthy control subjects, 47 subjects with
diabeteswithoutneuropathy,and58sub-
jects with diabetes and neuropathy (NDS
2) were included. Subjects with dia-
betic neuropathy were older and had
higher systolic blood pressures that those
without neuropathy or healthy control
subjects (P  0.01). In addition, all sub-
jectswithdiabetes(withandwithoutneu-
ropathy) had lower cholesterol and lower
LDL cholesterol levels than the healthy
control subjects (P  0.01). There were
no differences in BMI, weight, height, or
sex between groups. Diabetic subjects
with and without neuropathy had no dif-
ference in A1C or duration of diabetes.
Control subjects had lower body weights
and lower BMI and were younger than
diabetic subjects, although only age was
statistically different from subjects with
diabetes and neuropathy.
Neurophysiological testing
The results of all neurophysiological tests
bygroupareshowninTable2.Alltestsof
nerveconductionstudies,4of6measures
ofautonomicfunction,and9of11testsof
quantitative sensation differentiated dia-
betic subjects with neuropathy from
those without. Tests of cutaneous blood
ﬂow did not reliably differentiate diabetic
subjects with neuropathy from those
without. As revealed in Table 2, every test
differentiated healthy control subjects
from individuals with diabetic neuropa-
thy, except the change in systolic and di-
astolic blood pressures during tilt table
testing, the pain detection thresholds in
the upper limb, and the cutaneous blood
ﬂow changes (both endothelial depen-
dent and axon reﬂex mediated) in the up-
per limb.
Sensitivity and speciﬁcity
The tests with the highest sensitivity in-
cluded the blood pressure fall during
phase 2 of the Valsalva maneuver (89%)
and the cold-pain detection threshold in
the foot (89%). Tests with the highest
speciﬁcity included the Valsalva ratio
(78%), the peroneal amplitude (78%),
and the monoﬁlament detection thresh-
old (75%). The tests with the highest
overall sensitivity and speciﬁcity among
each testing modality included the Val-
salvaratio(73%sensitivityand78%spec-
iﬁcity) for autonomic studies, the
peronealcompoundmuscleactionpoten-
tial amplitude (73 and 78%) for nerve
conduction studies, monoﬁlament detec-
tion threshold (76 and 75%) for sensory
studies, and the direct blood ﬂow change
in the arm (77 and 60%) for cutaneous
Table 2—Neurophysiological function
Healthy control
Diabetes with
no neuropathy
Diabetes with
neuropathy
ROC
threshold Sensitivity Speciﬁcity
Autonomic testing
Phase 2 Valsalva maneuver blood pressure (mmHg) 1.80  0.40 1.33  0.71* 0.73  0.67*† 28 9 5 7
Valsalva ratio 1.54  0.23 1.50  0.29 1.26  0.21*† 1.3 73 78
Heart rate variability (bpm) 16.3  6.7 12.5  5.9 8.2  5.0*† 9.6 73 74
Valsalva phase 4 blood pressure overshoot 1.92  0.28 1.41  0.75* 0.86  0.87*† 27 0 6 7
Fall in systolic blood pressure during tilt (mmHg) 15.9  13.9 14.9  12.0 19.6  16.4 16 52 53
Change in heart rate during tilt (bpm) 16.0  8.5 14.6  8.5 7.7  13.7* 12 35 39
Nerve conduction studies
Peroneal amplitude (mV) 6.7  2.6 5.5  2.6 3.5  2.4*† 4.5 73 78
Sural amplitude (V) 10.7  8.0 7.5  6.5* 3.4  4.1*† 46 8 7 0
Peroneal velocity (m/s) 47.7  4.4 45.0  4.9 42.0  5.4*† 44 64 72
Peroneal distal latency (ms) 4.7  0.8 4.7  0.6 5.0  0.7*† 4.5 61 53
Sural velocity (m/s) 47.4  5.8 45.7  6.3 42.6  6.5*† 43 59 70
Sensory testing
Cold-pain foot (°C) 6.4  10.1 7.3  9.3 2.1  4.7*† 10 89 29
Heat-pain hand (°C) 46.0  4.5 45.5  4.5 46.8  3.2 45.1 80 41
Cold detection foot (°C) 25.7  7.0 25.3  6.4 17.2  10.5*† 25.5 77 70
Monoﬁlament threshold right (g) 3.76  0.4 3.8  0.5 4.7  1.3*† 4.1 76 75
Vibratory detection toe 4.8  7.4 5.2  7.6 20.6  26.0*† 4.3 76 72
Heat-pain foot (°C) 47.4  3.5 47.7  2.5 49.0  1.7*† 48.3 69 62
Heat detection hand (°C) 34.3  2.9 35.1  1.9 36.7  3.8*† 34.5 69 49
Heat detection foot (°C) 39.1  5.9 40.3  4.2 44.4  4.2*† 43 67 72
Vibratory detection thumb 1.0  0.5 2.0  2.5* 3.8  6.3*† 1.5 67 70
Cold detection hand (°C) 30.2  2.0 31.1  4.9 28.9  3.7† 30.2 61 72
Cold-pain hand (°C) 6.2  6.5 7.7  8.9 4.2  6.9* 36 1 5 4
Cutaneous blood ﬂow
Direct leg % change 248  285 202  205 114  159* 125% 77 60
Direct forearm % change 490  435 372  366 344  314 315% 55 50
Axon reﬂex leg % change 146  212 150  257 63  74* 75% 69 49
Axon reﬂex arm % change 291  354 412  920 720  3,370 220% 71 43
Data are means  SD or % for sensitivity and speciﬁcity. Characteristics of the study groups were compared by one-way ANOVA with Tamhane T2 post hoc tests.
ROC curves were generated with the selected maximal sensitivity and speciﬁcity for each test shown, and test values for the selection are reported as the ROC
threshold. *P  0.01 vs. healthy control subjects; †P  0.01 vs. diabetes without neuropathy.
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speciﬁcity for each test (against the NDS
score), categorized by neurophysiological
function is reported in Table 2.
Correlations between tests
Thehighestcorrelationwithinautonomic
tests was the heart rate variability and the
Valsalvaratio(r0.64).Thehighestcor-
relation between an autonomic test and
any other testing modality was the Val-
salva ratio and the sural SNAP (r  0.52).
The highest correlation within nerve con-
duction studies was the sural SNAP am-
plitude and sural nerve conduction
velocity (r  0.73). The highest correla-
tion with any other test was the sural
SNAP amplitude and Valsalva ratio (r 
0.52).Thehighestcorrelationwithinsen-
sory studies was the heat-pain detection
threshold in the hand and the cold-pain
detection threshold in the hand (r 
0.59). The highest correlation with any
othertestwasthesuralamplitudeandthe
monoﬁlament detection threshold (r 
0.44) and the cold detection in the foot
with the blood pressure overshoot during
phase 4 of the Valsalva maneuver (r 
0.44). The highest correlation within cu-
taneous blood ﬂow testing was the direct
and axon reﬂex–mediated blood ﬂow in
theleg(r0.34).Thehighestcorrelation
with any other test was the heat-pain de-
tection in the foot and the axon reﬂex–
mediated blood ﬂow in the leg (r 
0.29). A detailed matrix of the correla-
tions between and within groups is re-
ported in supplementary Tables 1–4,
available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc10-0763/DC1.
Cluster analysis
A two-step hierarchical cluster analysis
demonstrates the relative proximities of
each tested variable in the dendrogram of
Fig.1.Thedendrogramidentiﬁesthetests
thattrendtogether;themostdistalbranch
points reveal those tests that are most
closely associated. When individual pa-
tients, de-identiﬁed from a diagnosis of
neuropathy and diabetes, are assigned to
clusters based solely on neurophysiologi-
caldata,atotalofeightclustersofsubjects
emerge. The numbers of control and dia-
betic subjects (with and without neurop-
athy) assigned to each cluster are shown
in Fig. 2. Clusters 1 to 4 include all indi-
viduals (control and diabetic) without
neuropathy, whereas clusters 5 to 8 in-
clude those with neuropathy. The contri-
bution of each neurophysiological test
toward cluster assignment is also shown
in Fig. 2. The results indicate that rela-
tively few tests are required to separate
those individuals with neuropathy from
those without.
CONCLUSIONS— We present the
ﬁndings from a cross-sectional study of
diabetic neuropathy and neurophysiol-
ogy. In contrast to our hypothesis, our
results indicate that typical measures of
nerve ﬁber function do not necessarily
correlate together and that traditional
tests of large ﬁber neurophysiology (i.e.,
nerve conduction studies and vibration
detection thresholds) do not have higher
sensitivitiesandspeciﬁcitiesthansmallﬁ-
berorautonomictestscomparedwiththe
NDS examination score (a large ﬁber–
weighted examination score). Instead,
our results suggest a more complex rela-
tionship between tests of autonomic,
large, and small nerve ﬁbers in diabetic
neuropathy.
Our data also suggest that the use of a
single quantiﬁable examination or neuro-
physiological measure does not ade-
quately diagnose all presentations of
diabetic neuropathy (5,20,21). To iden-
tify the speciﬁc tests that provide the
greatest value in the differentiation of pa-
tients with neuropathy from those with-
out neuropathy, we used cluster analysis,
blinded to diabetes or neuropathy status,
to group individuals with similar neuro-
physiological characteristics. Individual
subjects were assigned to speciﬁc clusters
by weighted calculations from each neu-
rophysiological test. As outlined in Fig. 2,
the actual number of neurophysiological
variables that contribute to cluster forma-
tionisrelativelysmall,andonlyafewtests
are heavily weighted. The healthy sub-
jects fall into the ﬁrst four clusters, as do
most of the diabetic individuals without
clinical evidence of neuropathy. The last
four clusters are made up predominantly
of diabetic individuals that have clinical
evidence of neuropathy. These data sug-
gest that only a small number of neuro-
physiologicaltestsareactuallyrequiredto
differentiate individuals with neuropathy
from those without.
The dendrogram and cluster analysis
did not support the traditional categori-
zation of small, large, and autonomic
Figure1—Adendrogramhighlightingtheassociationbetweentestsusingatwo-stephierarchical
cluster analysis. Tests that cluster more closely together, such as the monoﬁlament of the left and
rightlegs,revealmoresimilartestresults.Manytestsfollowexpectedclustering,suchasheat-pain
detection in the hand and foot, sural amplitude and velocity, and systolic and diastolic blood
pressures.Otherteststhatwereexpectedtobemoresimilar,suchasvibrationdetectionandnerve
conduction studies, were not.
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tion testing. Correlation and cluster anal-
ysis suggested some unusual associations
that we did not predict before study initi-
ation. For example, as shown in the den-
drogram of Fig. 1, both nerve conduction
studies and vibration detection thresh-
olds are considered measures of large,
heavily myelinated nerve ﬁbers; however,
we found little association in the dendro-
gram between vibration detection and
nerve conduction studies. We found a
moredistalbranchingonthedendrogram
between nerve conduction studies and
heat detection in the feet. These ﬁndings
suggest a relationship that is more com-
plex than a simple description of small,
large, or autonomic neuropathy. Alterna-
tively, these neurophysiological tests may
not be speciﬁc for small, large, or auto-
nomic nerve ﬁber subtypes. In the ab-
sence of pathological conﬁrmation, we
areunabletodeterminewhethertestvari-
ation is due to nerve dysfunction, demy-
elination, or axonal loss.
We did note that certain tests are more
sensitive and speciﬁc for diagnosing the
presenceofneuropathy,whereasothertests
seem to be better at identifying subjects
without neuropathy. This observation is
highlighted in Fig. 2, in which we demon-
strate the relative importance of each spe-
ciﬁc test to cluster assignment. In cluster 1,
a very low vibration detection threshold
seems to be the single largest factor in iden-
tifying subjects without neuropathy. This
result may be explained by the ability of
subjects without neuropathy to quickly de-
tect a stimulus using a method of limits ap-
Figure2—Thisﬁgurereportseightclusters(C1–C8)ofindividualsfromthestudy.Thenumbersofhealthycontrolanddiabeticsubjectswithandwithout
neuropathyareshownforeachcluster.Clusters1–4aremadeupofhealthycontrolsubjectsandsubjectswithoutneuropathy,whereasclusters5–8aremade
up of individuals with neuropathy. The tests that contributed to the formation of these clusters are listed in the lower portion of the table, with circle size
demonstrating the relative weight of each test toward a particular cluster assignment: the larger the circle, the greater the weight. Black indicates a more
normal (i.e., better) result, and white indicates a more abnormal (i.e., worse) result. For example, the large black circle on vibration detection at the toe
indicates that a good result was the single most important factor in assigning individuals to cluster 1. Cluster 1 seems to be made up of individuals with
entirely normal responses; clusters 2 and 4 are individuals with normal sensation and autonomic testing but some reduced vasomotor blood ﬂow. Cluster3
contains healthy individuals who have some decreased cold-pain detection. Cluster 5 indicates individuals with modest neuropathy across all neurophysi-
ologic tests, while cluster 7 indicates those with autonomic neuropathy. Cluster 6 indicated signiﬁcant neuropathy across all neurophysiologic tests with
predominant “small nerve ﬁber” dysfunction, while cluster 8 indicates more “large nerve ﬁber” dysfunction.
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subjects with neuropathy, the testing dura-
tion increases, as does response variability,
because of the psychophysical nature of the
method (22).
Some of the variability among tech-
niques may also be explained by the psy-
chophysical component of sensory tests.
All measurements of small ﬁber sensory
function require a subjective response
from subjects and may be diminished in
conditions of fatigue or illness. Other
tests,suchaslaserDopplerﬂowmetry,are
impartial measurements of small ﬁber
functionandprovideresultsindependent
of subject attention. Theoretically, this
gives laser Doppler ﬂowmetry an advan-
tage over sensory tests by providing a
purely objective measurement of c-ﬁber
function and the ability to detect early
signs of neuropathy development.
We also noted a very interesting dif-
ference in baseline characteristics be-
tween groups: the total cholesterol and
LDL cholesterol levels in patients with di-
abetes were lower than those in the
healthy control subjects. Although these
values reﬂect modern aggressive treat-
ment of patients with diabetes, it is likely
tohaveanimpactonthenaturalhistoryof
the disease compared with an untreated
state.However,aggressivetreatmentofall
causative factors (smoking, blood pres-
sure, lipids, and others) is now the stan-
dardofclinicalcareandwillbeimportant
to consider in the expected outcomes of
longitudinal studies of diabetes and neu-
ropathy. In particular, the effects of lipid
control on the development of small ﬁber
neuropathy will be of interest (23–25).
Insummary,themodestcorrelationco-
efﬁcients seen among the different testing
modalities suggest that these techniques
measure different neurophysiological pa-
rameters and are therefore not interchange-
able. In addition, the natural clustering of
both patients and healthy control subjects
into speciﬁc subgroups suggests that varia-
tionsinthepopulationwillneedtobetaken
into account when one is selecting subjects
for speciﬁc studies.
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